Arsanis yanks phase II study of ASN-100 after interim look heralds futility + | BioWorldSubscribeBioWorld - Monday, May 11, 2020Home Arsanis yanks phase II study of ASN-100 after interim look heralds futilityLooking to read the full article? Subscribe to BioWorld.Arsanis yanks phase II study of ASN-100 after interim look heralds futility June 29, 2018 By Marie Powers No CommentsThe future of ASN-100, the lead and only clinical candidate at Arsanis Inc., is in doubt after the Waltham, Mass.-based company halted the phase II test of the hemolysin alpha inhibitor for the prevention of Staphylococcus aureus (S. aureus) pneumonia in hospitalized, mechanically ventilated patients. A planned interim analysis of unblinded data by an independent data review committee (DRC) concluded the study was unlikely to meet its primary efficacy endpoint of preventing the virulent infection for up to 21 days in heavily colonized patients following a single intravenous administration, dosed at 20 mg. BioWorld

>>> 更多资讯详情请访问蚂蚁淘商城